The results could open the door to new targeted therapies for this debilitating disease in the future
In the largest study of its kind, nine novel genes for osteoarthritis have been discovered by scientists from the Wellcome Sanger Institute and their collaborators. Results of the study, published today (19 March) in Nature Genetics, could open the door to new targeted therapies for this debilitating disease in the future.
Almost nine million people in the UK suffer from osteoarthritis, a degenerative joint disease in which a person’s joints become damaged, stop moving freely and become painful. Osteoarthritis is the most prevalent musculoskeletal disease and a leading cause of disability worldwide.
There is no treatment for osteoarthritis. The disease is managed with pain relief and culminates in joint replacement surgery, which has variable outcomes.
In the largest study of its kind, scientists from the Wellcome Sanger Institute and their collaborators* investigated the genetics behind osteoarthritis, as well as the diseases and traits that are linked to it.
To understand more about the genetic basis of osteoarthritis, the team studied 16.5 million DNA variations from the UK Biobank resource. Following combined analysis in up to 30,727 people with osteoarthritis and nearly 300,000 people without osteoarthritis in total – the controls – scientists discovered nine new genes that were associated with osteoarthritis, a significant result for this disease.
“Osteoarthritis is challenging to study because the disease can vary among people, and also between the different joints affected, for example knee, hip, hand and spine. Using data from the UK Biobank resource, we have undertaken the largest genetic study of osteoarthritis to date and uncovered nine new genes associated with the disease.”
Professor Eleftheria Zeggini, senior author from the Wellcome Sanger Institute
Researchers then investigated the role of the nine new genes in osteoarthritis, by studying both normal cartilage and diseased cartilage from individuals who had a joint replacement.
The team looked for genes that were active in the progression of the disease by extracting the relevant cells from healthy and diseased tissue, studying the levels of proteins in the tissue and sequencing the RNA – the messenger that carries instructions from DNA for controlling the production of proteins.
Of the nine genes associated with osteoarthritis, researchers identified five genes in particular that differed significantly in their expression in healthy and diseased tissue. The five genes present novel targets for future research into therapies.
“These results are an important step towards understanding the genetic causes of osteoarthritis and take us closer to uncovering the mechanism behind the disease. Once we know that, it opens the door to developing new therapies for this debilitating disease.”
Ms Eleni Zengini, joint first author from the University of Sheffield and Dromokaiteio Psychiatric Hospital in Athens
The team also explored genetic correlations between osteoarthritis and obesity, bone mineral density, type 2 diabetes, and raised blood lipid levels.
Researchers applied a statistical technique known as causal inference analysis to uncover which traits and diseases cause osteoarthritis, and which do not.
Within the limits of their study, scientists discovered that type 2 diabetes and high levels of lipids in the blood do not have causal effects on osteoarthritis, but reaffirm that obesity does.
“Using genetic data, we have shown that type 2 diabetes and increased blood lipid levels do not appear to be on the causal path to osteoarthritis. We also reconfirmed that obesity is on the causal path to osteoarthritis.”
Dr Konstantinos Hatzikotoulas, joint first author from the Wellcome Sanger Institute
“The discovery of these genes is positive news for the 8.5 million people in the UK living with osteoarthritis. People living with this debilitating condition currently have limited treatment options. Meanwhile, they can struggle to do the day-to-day things most of us take for granted, like going to work or getting dressed independently. By revealing how these genes contribute to osteoarthritis, this research could open the door for new treatments to help millions of people live the pain free life they deserve.”
Dr Natalie Carter, Head of research liaison & evaluation at Arthritis Research UK, who did not fund the study
Learn more: New osteoarthritis genes discovered
The Latest on: Osteoarthritis
via Google News
The Latest on: Osteoarthritis
Erratum: Predictors and Outcomes of Crossover to Surgery from Physical Therapy for Meniscal Tear and Osteoarthritis
on July 18, 2018 at 11:51 am
In the article entitled “Predictors and Outcomes of Crossover to Surgery from Physical Therapy for Meniscal Tear and Osteoarthritis: A Randomized Trial Comparing Physical Therapy and Surgery” (J Bone ... […]
Positive Phase 3 Results for Novel OA Pain Treatment Tanezumab
on July 18, 2018 at 10:03 am
Pfizer and Lilly announced positive results from a Phase 3 study (A4091056) evaluating tanezumab, an investigational humanized monoclonal antibody, for the treatment of osteoarthritis (OA) pain. The 1... […]
Visual illusion proves effective in relieving knee pain for people with osteoarthritis
on July 18, 2018 at 5:17 am
In a new study published in the journal Peer J this week, researchers at UniSA's Body in Mind Research Group have found people suffering osteoarthritis in the knees reported reduced pain when exposed ... […]
Pfizer and Lilly's tanezumab successful in late-stage osteoarthritis pain study
on July 18, 2018 at 4:32 am
Pfizer (NYSE:PFE) and development partner Eli Lilly (NYSE:LLY) announce positive results from a Phase 3 clinical trial evaluating subcutaneously administered tanezumab for the treatment of osteoarthri... […]
Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
on July 18, 2018 at 4:01 am
Pfizer Inc.(PFE) and Eli Lilly and Company (LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investig... […]
Illusory resizing of the painful knee is analgesic in symptomatic knee osteoarthritis
on July 17, 2018 at 1:25 am
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for ... […]
British Open 2018: John Daly withdraws due to bad knee, says 'osteoarthritis is unbearable'
on July 15, 2018 at 1:31 pm
John Daly has withdrawn from the 2018 Open Championship, citing "unbearable" osteoarthritis in his right knee. The not-so-surprising news continues what has been a frustrating season for the 1995 Open ... […]
Osteoarthritis Pain Market in Europe to 2026: Analysis on Epidemiology, Patient Flow, Prevalence and Diagnosed & Treated Patients
on July 13, 2018 at 3:11 pm
The "Europe Osteoarthritis Pain Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering. The research provides insights into Osteoarthritis Pain epide... […]
Europe Osteoarthritis Pain Epidemiology & Patient Flow Analysis - 2018 - ResearchAndMarkets.com
on July 13, 2018 at 5:58 am
DUBLIN--(BUSINESS WIRE)--The "Europe Osteoarthritis Pain Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering. The research provides insights into ... […]
via Bing News